Ultravist

Ultravist is a brand name of iopromide, approved by the FDA in the following formulation(s):

ULTRAVIST 150 (iopromide - injectable; injection)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: May 10, 1995
  
  Strength(s): 31.2% ^[RLD]


• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: May 10, 1995
  
  Strength(s): 49.9% ^[RLD]


• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: May 10, 1995
  
  Strength(s): 62.3% ^[RLD]


• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: May 10, 1995
  
  Strength(s): 76.9% ^[RLD]

Has a generic version of Ultravist been approved?

No. There is currently no therapeutically equivalent version of Ultravist available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultravist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ultravist.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 30, 2012 - INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
  
  

See also...